Rabies deaths in Pakistan: results of ineffective post-exposure treatment

被引:36
作者
Parviz, S [1 ]
Chotani, R
McCormick, J
Fisher-Hoch, S
Luby, S
机构
[1] Aga Khan Univ, Dept Community Hlth Sci, Karachi 74800, Pakistan
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA
[4] Aga Khan Univ, Dept Pathol, Karachi, Pakistan
关键词
rabies; sheep brain vaccine; vaccine efficacy; incidence; Pakistan; developing country; cold chain;
D O I
10.1016/j.ijid.2004.02.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To estimate the incidence of rabies and the effectiveness of post-exposure treatment (PET) in Pakistan. Methods: Rabies cases admitted from July 1993 to December 1994 to a public rabies isolation hospital were analyzed. Two samples (one sample each from a separate peripheral site) of a single batch of sheep brain vaccine (SBV) were also tested for potency by the National Institute of Health (NIH) test in May 1997. Results: Forty patients were admitted with a history of clinical rabies. The median age was 22 years and 55% were under 15. Thirteen (23%) victims did not receive any vaccine; the remaining 27 (67%) received SBV only, and of these, 16 (40%) received a full course of SBV. No rabies immunoglobutins (RIG) or cell culture vaccines were administered. There were frequent power blackouts and no back-up supply at the public hospital. In-house potency testing of the vaccine batch by the manufacturer was adequate, athough it was not tested by the World Health Organization (WHO) recommended NIH test. Samples of SBV of the same batch collected at the peripheral sites showed no potency. Rabies incidence was estimated to range between 7.0 to 9.8 cases per million annually. Conclusion: A multi-sectorial approach is needed to decrease rabies incidence in Pakistan. Public and healthcare practitioner education on prompt and appropriate PET, especially the use of cost-effective cell culture intradermal regimens, is needed urgently. The NIH test should be employed for vaccine potency testing. An independent agency is needed for monitoring vaccine quality and strategies are needed for maintaining cold chain. SBV should be replaced by locally manufactured second-generation cell culture rabies vaccine. Purified equine rabies immunoglobulin (ERIG) should be manufactured locally to meet national needs. Furthermore, effective dog control strategies should be implemented to decrease the rabies reservoir. (C) 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 44 条
[1]   NEUROPARALYTIC COMPLICATIONS AFTER ANTIRABIES VACCINE (INACTIVATED NERVOUS-TISSUE VACCINE) [J].
AHASAN, HAMN ;
CHOWDHURY, MAJ ;
AZHAR, MA ;
RAFIQUEUDDIN, AKM .
TROPICAL DOCTOR, 1995, 25 (02) :94-94
[2]  
ARYA S C, 1991, Indian Journal of Pediatrics, V58, P563, DOI 10.1007/BF02820173
[3]   SUCCESSFUL PROTECTION OF HUMANS EXPOSED TO RABIES INFECTION - POSTEXPOSURE TREATMENT WITH NEW HUMAN DIPLOID CELL RABIES VACCINE AND ANTIRABIES SERUM [J].
BAHMANYAR, M ;
FAYAZ, A ;
NOURSALEHI, S ;
MOHAMMADI, M ;
KOPROWSKI, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 236 (24) :2751-2754
[4]  
BALTAZARD M, 1954, Bull World Health Organ, V10, P797
[5]  
BARTH R, 1983, LANCET, V1, P700
[6]  
BOGEL K, 1986, B WORLD HEALTH ORGAN, V64, P883
[7]  
Burney M I, 1976, Trop Doct, V6, P60
[8]  
Burney M I, 1993, Int J Technol Assess Health Care, V9, P397
[9]   A study of human rabies immune globulin manufactured by the Thai Red Cross [J].
Chantanakajornfung, A ;
Naraporn, N ;
Khumphai, W ;
Bejavongkulchai, M ;
Mitmoonpitak, C ;
Wilde, H .
VACCINE, 1999, 17 (7-8) :979-981
[10]   Vaccine safety: Current and future challenges [J].
Chen, RT ;
Hibbs, B .
PEDIATRIC ANNALS, 1998, 27 (07) :445-455